

Commission Regulation (EU) 2020/878

Fidaxomicin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	4757498-00012	Date of first issue: 15.08.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier		
	Trade name	:	Fidaxomicin Solid Formulation
1.2	Relevant identified uses of th	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
1.3	Details of the supplier of the Company	saf	ety data sheet MSD
1.3		saf	MSD Piercetown
1.3		saf	MSD
1.3		:	MSD Piercetown
1.3	Company	:	MSD Piercetown A86 HD21 Dunboyne, Ireland

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

	unoc						
Classification (REGULATION (EC) No 1272/2008) Acute toxicity, Category 4 H302: Harmful if swallowed.							
2.2 Label elements							
Labelling (REGULATION Hazard pictograms	(EC) :	No 1272/200)8)				
Signal word	:	Warning					
Hazard statements	:	H302	Harmful if swallowed.				

Precautionary statements : Prevention:



Fidaxomicin Solid Formulation

Version 3.1	Revision Date: 28.09.2024	SDS Number: 4757498-00012	Date of last issue: 06.04.2024 Date of first issue: 15.08.2019
			ash skin thoroughly after handling. not eat, drink or smoke when using this prod-
			P330 IF SWALLOWED: Call a POISON NTER/ doctor if you feel unwell. Rinse mouth.

Hazardous components which must be listed on the label:

Fidaxomicin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components			
Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Fidaxomicin	873857-62-6	Acute Tox. 4; H302	>= 50 - < 70
Sodium benzoate	532-32-1 208-534-8	Eye Irrit. 2; H319	>= 1 - < 10
Citric acid	77-92-9 201-069-1 607-750-00-3	Eye Irrit. 2; H319 STOT SE 3; H335	>= 1 - < 10

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Fidaxomicin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	4757498-00012	Date of first issue: 15.08.2019

SECTION 4: First aid measures

4.1 Description of first aid measures				
General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.		
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).		
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.		
In case of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.		
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.		
If swallowed	:	If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.		
4.2 Most important symptoms a	nd e	effects, both acute and delayed		
Risks	:	Harmful if swallowed.		
		Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.		
	me	dical attention and special treatment needed		
Treatment	:	Treat symptomatically and supportively.		

SECTION 5: Firefighting measures

media

5.1 Extinguishing media		
Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing	:	None known.



Fidaxomicin Solid Formulation

Ver 3.1	sion	Revision Date: 28.09.2024		DS Number: 57498-00012	Date of last issue: 06.04.2024 Date of first issue: 15.08.2019
5.2	Special	hazards arising from	the	e substance or mi	xture
	Specifi fighting	•	:	Exposure to com	pustion products may be a hazard to health.
	Hazardous combustion prod- ucts		:	Carbon oxides Metal oxides Chlorine compounds	
5.3	Advice	for firefighters			
		l protective equipment ighters	:		e, wear self-contained breathing apparatus. ective equipment.
	Specifi ods	c extinguishing meth-	:	cumstances and Use water spray f	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

cannot be contained.

Local authorities should be advised if significant spillages

6.3 Methods and material for containment and cleaning up

	 Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
--	--

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	4757498-00012	Date of first issue: 15.08.2019

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

	Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding
	Local/Total ventilation Advice on safe handling	:	and bonding, or inert atmospheres. Use only with adequate ventilation. Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment
			Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
	Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
7.2	Conditions for safe storage, i	ncl	uding any incompatibilities
	Requirements for storage areas and containers	:	Keep in properly labelled containers. Store in accordance with the particular national regulations.
	Advice on common storage	:	Do not store with the following product types:

7.3 Specific end use(s)

Specific use(s) : No data available

Strong oxidizing agents



Fidaxomicin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	4757498-00012	Date of first issue: 15.08.2019

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Fidaxomicin	873857-62- 6	TWA	200 µg/m3 (OEB 2)	Internal
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Sodium benzoate	Workers	Inhalation	Long-term systemic effects	3 mg/m3
	Workers	Inhalation	Long-term local ef- fects	0.1 mg/m3
	Workers	Skin contact	Long-term systemic effects	62.5 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	1.5 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	0.06 mg/m3
	Consumers	Skin contact	Long-term systemic effects	31.25 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	16.6 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Citric acid	Fresh water	0.44 mg/l
	Marine water	0.044 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	34.6 mg/kg dry
		weight (d.w.)
	Marine sediment	3.46 mg/kg dry
		weight (d.w.)
	Soil	33.1 mg/kg dry
		weight (d.w.)
Sodium citrate	Fresh water	0.44 mg/l
	Marine water	0.044 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	34.6 mg/kg dry
		weight (d.w.)
	Marine water	3.46 mg/kg dry
		weight (d.w.)
	Soil	31.1 mg/kg dry
		weight (d.w.)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
3.1		4757498-00012	Date of first issue: 15.08.2019

Sodium benzoate	Fresh water	0.13 mg/l
	Freshwater - intermittent	0.305 mg/l
	Marine water	0.013 mg/l
	Sewage treatment plant	10 mg/l
	Fresh water sediment	1.76 mg/kg dry weight (d.w.)
	Marine sediment	0.176 mg/kg dry weight (d.w.)
	Soil	0.276 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	300 mg/kg food

8.2 Exposure controls

Engineering measures

Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection Material	:	Chemical-resistant gloves
Skin and body protection Respiratory protection	:	Work uniform or laboratory coat. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	granules
Colour	:	White to light yellow
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Vers 3.1	sion	Revision Date: 28.09.2024		S Number: 57498-00012	Date of last issue: 06.04.2024 Date of first issue: 15.08.2019
				dling or other me	eans.
	Flamm	ability (liquids)	:	No data available	e
		explosion limit / Upper ability limit	:	No data available	9
		explosion limit / Lower ability limit	:	No data available	9
	Flash p	point	:	Not applicable	
	Auto-ig	nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	рН		:	No data available	9
	Viscosi Visc	ity cosity, kinematic	:	Not applicable	
	Solubil Wat	ity(ies) ter solubility	:	No data available	9
	Partitio octano	n coefficient: n- I/water	:	Not applicable	
	Vapour	rpressure	:	Not applicable	
	Relativ	e density	:	No data available	9
	Density	/	:	No data available	9
	Relativ	e vapour density	:	Not applicable	
		e characteristics ticle size	:	No data available)
9.2	9.2 Other information				
	Explos		:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Evapor	ation rate	:	Not applicable	
	Molecu	ılar weight	:	No data available	9

Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	4757498-00012	Date of first issue: 15.08.2019

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions	 May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
10.4 Conditions to avoid	
Conditions to avoid	: Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid	: Oxidizing agents
--------------------	--------------------

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
Acute toxicity Harmful if swallowed.		
Product:		
Acute oral toxicity	:	Acute toxicity estimate: 875.04 mg/kg Method: Calculation method
Components:		
Fidaxomicin:		
Acute oral toxicity	:	LD50 (Rat): > 1,000 mg/kg
		LD50 (Dog): > 120 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Rat): 200 mg/kg Application Route: Intravenous
,		

Sodium benzoate:



sion	Revision Date: 28.09.2024		Number:Date of last issue: 06.04.202498-00012Date of first issue: 15.08.2019
Acute	oral toxicity		050 (Rat): > 2,000 mg/kg sessment: The substance or mixture has no acute oral to ty
Acute	dermal toxicity		950 (Rabbit): > 2,000 mg/kg emarks: Based on data from similar materials
Citric	acid:		
Acute	oral toxicity	: LC	950 (Mouse): 5,400 mg/kg
Acute	dermal toxicity	Me As	950 (Rat): > 2,000 mg/kg ethod: OECD Test Guideline 402 sessment: The substance or mixture has no acute derma kicity
-	corrosion/irritation assified based on ava	ailable info	rmation.
<u>Comp</u>	onents:		
Sodiu	m benzoate:		
Specie	es	: Ra	abbit
Metho			ECD Test Guideline 404
Result	t	: NC	skin irritation
Citric	acid:		
Specie			abbit
Metho Result			ECD Test Guideline 404
	u s eye damage/eye assified based on ava		rmotion
	ionents:		
	m benzoate:		
Specie		: Ra	abbit
Metho	d	: OI	ECD Test Guideline 405
Result	t	: Irr	tation to eyes, reversing within 21 days
Citric	acid:		
Specie			abbit
Metho		-	ECD Test Guideline 405
Result	t	: Irr	tation to eyes, reversing within 21 days
Respi	ratory or skin sensi	tisation	
-			

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	4757498-00012	Date of first issue: 15.08.2019

Respiratory sensitisation

Not classified based on available information.

Components:

Sodium benzoate:

Test Type :	Local lymph node assay (LLNA)
Exposure routes :	Skin contact
Species :	Mouse
Result :	negative
Remarks :	Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Fidaxomicin:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: positive
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Application Route: Intravenous Result: negative
		Test Type: comet assay Species: Rat Result: negative
Sodium benzoate:		
Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosome aberration test in vitro Result: positive
Genotoxicity in vivo	:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative
Citric acid:		
Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



in vivo icity d based on availa	:	Result: positive Test Type: Bacte Result: negative Test Type: Mutag	o micronucleus test erial reverse mutation assay (AMES) genicity (in vivo mammalian bone-marrow chromosomal analysis) e: Ingestion
icity	:	Result: positive Test Type: Bacte Result: negative Test Type: Mutag cytogenetic test, Species: Rat Application Route	erial reverse mutation assay (AMES) genicity (in vivo mammalian bone-marrow chromosomal analysis)
icity	:	Result: negative Test Type: Mutag cytogenetic test, Species: Rat Application Route	genicity (in vivo mammalian bone-marrow chromosomal analysis)
icity	:	cytogenetic test, Species: Rat Application Route	chromosomal analysis)
•			C C
	ahle	information	
<u>s:</u>	2010		
120410.	:	Rat	
	:	Ingestion	
ne	:		
•			
	able	information.	
<u>s:</u>			
rtility	:		ty/early embryonic development
		Application Route	e: Intravenous injection
		Fertility: NOAEL:	6.3 mg/kg body weight
etal develop-	:		yo-foetal development
		Species: Rat	a: Intravenous injection
			oxicity: NOAEL: 12.6 mg/kg body weight
			nificant adverse effects were reported
			yo-foetal development
			o: Introveneure injection
		Developmental T	Foxicity: NOAEL: 7 mg/kg body weight nificant adverse effects were reported
vzoste:			
	:	Test Type: Four-	generation reproduction toxicity study
· · · · · · · · ·	-	Species: Rat	
			e: Ingestion
	nzoate: Route ne ve toxicity	Azoate:	image: Sector of the sector



	Revision Date: 28.09.2024	SDS Number: 4757498-00012	Date of last issue: 06.04.2024 Date of first issue: 15.08.2019
		Remarks: Base	ed on data from similar materials
Effec ment	ets on foetal develop-	: Test Type: Em Species: Rat Application Ro Result: negativ	
Citri	c acid:		
Effec ment	ts on foetal develop-	: Test Type: One Species: Rat Application Ro Result: negativ	
	T - single exposure classified based on ava	ilable information.	
	ponents:		
	c acid: essment	: May cause res	piratory irritation.
Done	ated dese texicity		
Com	eated dose toxicity ponents:		
Com Fida Spec NOA Appli	xomicin: cies EL ication Route osure time	: Rat : 90 mg/kg : Oral : 28 D : No significant a	adverse effects were reported
Com Fida Spec NOA Appli Expo Rem Spec NOA Appli	ponents: xomicin: cies EL ication Route osure time arks	: 90 mg/kg : Oral : 28 D	adverse effects were reported
Com Fida Spec NOA Appli Expo Rem Spec NOA Appli Expo Spec NOA Appli Expo	xomicin: xomicin: EL ication Route osure time arks EL ication Route osure time cies EL ication Route osure time ptoms	 90 mg/kg Oral 28 D No significant a Rat 62.5 mg/kg Intravenous 14 D Dog 9,600 mg/kg Oral 3 M Vomiting 	adverse effects were reported

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 3.1	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.20244757498-00012Date of first issue: 15.08.2019
NO/ App Exp	cies AEL lication Route osure time narks	 Juvenile rat 200 mg/kg Oral 28 D No significant adverse effects were reported
Spe NO/ App	lium benzoate: cies AEL lication Route osure time	: Rat : 1,000 mg/kg : Ingestion : 24 Months
Spe NO/ LO/ App	ic acid: cies AEL AEL lication Route osure time	: Rat : 4,000 mg/kg : 8,000 mg/kg : Ingestion : 10 Days
Not	viration toxicity classified based on ava prmation on other haza	
Enc	locrine disrupting pro	erties
	<u>duct:</u> essment	: The substance/mixture does not contain components consid ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 a levels of 0.1% or higher.
Exp	erience with human e	posure
<u>Cor</u>	nponents:	
	axomicin: estion	: Symptoms: Abdominal pain, Nausea, Vomiting, constipation
SECTIC	N 12: Ecological inf	rmation
12.1 Tox	licity	
	nponents:	
	axomicin:	
Tox plar	icity to algae/aquatic its	 EC50 (Anabaena flos-aquae (cyanobacterium)): > 18.4 mg/l Exposure time: 72 h Method: OECD Test Guideline 201



limit of solubility ae (cyanobacterium)): 5.8 mg/l
ae (cyanobacterium)): 5.8 mg/l
line 201 limit of solubility
bition line 209
bition line 209
elas (fathead minnow) line 210 limit of solubility
Water flea) line 211
as (fathead minnow)): 484 mg/l
ater flea)): > 100 mg/l
subcapitata (green algae)): > 100 line 201
a subcapitata (green algae)): 32 line 201
as (fathead minnow)): > 100 mg/l
ater flea)): 1,535 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fidaxomicin Solid Formulation

Version 3.1	Revision Date: 28.09.2024		DS Number: 757498-00012	Date of last issue: 06.04.2024 Date of first issue: 15.08.2019
12.2 Per	sistence and degradabi	ility		
<u>Con</u>	nponents:			
	ium benzoate: legradability	:	Result: Readily b Biodegradation: Exposure time: 2	75 %
Citri	ic acid:			
Bioc	legradability	:	Result: Readily b Biodegradation: Exposure time: 2 Method: OECD 1	97 %
12.3 Bioa	accumulative potential			
<u>Con</u>	nponents:			
Part	ixomicin: ition coefficient: n- nol/water	:	log Pow: 4.4	
Part	ium benzoate: ition coefficient: n- nol/water	:	log Pow: 1.88	
Part	i c acid: ition coefficient: n- nol/water	:	log Pow: -1.72	
12.4 Mot	pility in soil			
<u>Con</u>	<u>nponents:</u>			
Dist	ixomicin: ribution among environ- tal compartments	:	log Koc: 0.80	
12.5 Res	ults of PBT and vPvB a	isse	essment	
	<u>duct:</u> essment	:	to be either persi	nixture contains no components considered istent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of
12.6 End	locrine disrupting prop	ertie	es	
	duct:			
	essment		The substance/m	nixture does not contain components consid-

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation



Fidaxomicin Solid Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
3.1		4757498-00012	Date of first issue: 15.08.2019

(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good

14.4 Packing group

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Fidaxomicin Solid Formulation

Version 3.1	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.20244757498-00012Date of first issue: 15.08.2019		
ADN		: Not regulated as a dangerous good		
ADR		: Not regulated as a dangerous good		
RID		: Not regulated as a dangerous good		
IMDG	6	: Not regulated as a dangerous good		
ΙΑΤΑ	(Cargo)	: Not regulated as a dangerous good		
ΙΑΤΑ	(Passenger)	: Not regulated as a dangerous good		
14.5 Envi	ronmental hazards			
Not regulated as a dangerous good				
14.6 Spec	ial precautions for u	er		

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances,	:	Conditions of restriction for the fol- lowing entries should be considered:
mixtures and articles (Annex XVII)		Number on list 75: If you intend to
		use this product as tattoo ink, please

here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

Substance(s) or mixture(s) are listed

contact your vendor.

REACH - Candidate List of Substances of Very High	
Concern for Authorisation (Article 59).	

Regulation (EC) on substances that deplete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollutants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals

REACH - List of substances subject to authorisation (Annex XIV)

- : Not applicable



Fidaxomicin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	4757498-00012	Date of first issue: 15.08.2019

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. Not applicable

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information				
Other information	:	Items where cha		

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H302	:	Harmful if swallowed.
H319	:	Causes serious eye irritation.
H335	:	May cause respiratory irritation.
Full text of other abbreviatio	ns	
Acute Tox.	:	Acute toxicity
Eye Irrit.	:	Eye irritation
STOT SE	:	Specific target organ toxicity - single exposure
IE OEL	:	Ireland. List of Chemical Agents and Carcinogens with Occu-
		pational Exposure Limit Values - Code of Practice, Schedule 1 and 2
IE OEL / OELV - 8 hrs (TWA)	:	Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test popula-



Fidaxomicin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.1	28.09.2024	4757498-00012	Date of first issue: 15.08.2019

tion; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data		eChem Portal search results and European Chemicals Agen-
Sheet		cy, http://echa.europa.eu/

Acute Tox. 4 H302

Classification procedure: Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN